Companies: 10,795·Total market cap: $144.5T
Vor Biopharma Inc.

Vor Biopharma Inc.

VORNASDAQHealthcare● Active
$13.29
+$0.13(+0.99%)
Market Cap$91088411
P/E Ratio
52W High$65.8
52W Low$3.62
Overview

Vor Biopharma Inc. (VOR) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

vor · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Vor Biopharma Inc. (VOR) measures how much investors pay for each dollar of the company's trailing earnings. VOR's current PE ratio of N/A is calculated by dividing its stock price of $13.29 by its TTM earnings per share of -$2053.13.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-3.48
Based on 6 analysts
EPS (TTM)
-$2053.13
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vor Biopharma Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Vor Biopharma Inc.
Vor Biopharma Inc.You
VOR
$91MN/A-$2053.13
Actuate Therapeutics Inc
Actuate Therapeutics Inc
ACTU
$44MN/A-$1.06
Alector, Inc.
Alector, Inc.
ALEC
$182MN/A-$1.39
Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
ANIX
$82MN/A-$0.34
Applied Therapeutics, Inc.
Applied Therapeutics, Inc.
APLT
$15MN/A-$0.76
Fate Therapeutics, Inc.
Fate Therapeutics, Inc.
FATE
$223MN/A-$1.15
Forte Biosciences, Inc.
Forte Biosciences, Inc.
FBRX
$218MN/A-$0.47

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-70.50
2024-12-31
FY2024
$-34.03
2023-12-31
FY2023
$-35.08
2022-12-31
FY2022
$-46.57
2021-12-31
FY2021
$-37.07
2020-12-31
FY2020
$-23.34
2019-12-31
FY2019
$-5.84
2018-12-31
FY2018
$-14.67

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Vor Biopharma Inc. (VOR) measures how much investors pay for each dollar of the company's trailing earnings. VOR's current PE ratio of N/A is calculated by dividing its stock price of $13.29 by its TTM earnings per share of -$2053.13.

PE Ratio = Stock Price ÷ EPS (TTM)
= $13.29 ÷ -$2053.13 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

VOR pe ratio · 6 questions

VOR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $13.29 and TTM EPS of -$2053.13. Data sourced from Financial Modeling Prep via VOR's SEC 10-K and 10-Q filings.

VOR PE ratioWhat is VOR PE ratioCurrent PE ratio of VORVOR PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vor Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09